Evidence map›Paper›PMID 35630476›Full record

ArticleMicroorganisms2022

Enhanced Immunogenicity of Inactivated Dengue Vaccines by Novel Polysaccharide-Based Adjuvants in Mice.

Shuenn-Jue Wu, Dan Ewing, Appavu K Sundaram, Hua-Wei Chen, Zhaodong Liang, Ying Cheng, Vihasi Jani, Peifang Sun, Gregory D Gromowski, Rafael A De La Barrera and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Shuenn-Jue WuViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.ORCID 0000-0003-3369-4259
Dan EwingViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Appavu K SundaramViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Hua-Wei ChenViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Zhaodong LiangViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Ying ChengViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Vihasi JaniViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Peifang SunViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0003-4576-4277
Rafael A De La BarreraPilot Bioproduction Facility, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Megan A SchillingViral and Rickettsial Diseases Department, Infectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Nikolai PetrovskyVaxine Pty Ltd., Warradale, SA 5042, Australia.ORCID 0000-0002-1580-5245
Kevin R PorterInfectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Maya WilliamsInfectious Diseases Directorate, Naval Medical Research Center, Silver Spring, MD 20910, USA.
Naval Medical Research Command · USHenry M. Jackson Foundation · USWalter Reed Army Institute of Research · USFlinders University · AULeidos (United States) · US

Funding

Military Infectious Diseases Research Program S0638_19_NMNational Institute of Allergy and Infectious Diseases HHS-N272201400053C and HHS-N272200800039C
6 · The paper itself

Abstract

Dengue fever, caused by any of four dengue viruses (DENV1-4), is a major global burden. Currently, there is no effective vaccine that prevents infection in dengue naïve populations. We tested the ability of two novel adjuvants (Advax-PEI and Advax-2), using aluminum hydroxide (alum) as control, to enhance the immunogenicity of formalin- or psoralen-inactivated (PIV or PsIV) DENV2 vaccines in mice. Mice were vaccinated on days 0 and 30, and serum samples were collected on days 30, 60, 90, and 101. Neutralizing antibodies were determined by microneutralization (MN) assays, and the geometric mean 50% MN (MN

Indexed as

Advax™ adjuvantsdengue vaccinedengue virusformalin inactivationpolysaccharide-based adjuvantspsoralen inactivation

Identifiers

PMID35630476
PMCPMC9146336
OpenAlexW4280598540

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.